ClinicalTrials.Veeva

Menu

Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid (INWARA)

A

Assistance Publique - Hôpitaux de Paris

Status and phase

Completed
Phase 4

Conditions

Pulmonary Embolism
Atrial Fibrillation
Deep Venous Thrombosis
Oral Anticoagulation

Treatments

Drug: Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo
Drug: Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid

Study type

Interventional

Funder types

Other

Identifiers

NCT00603317
P051056

Details and patient eligibility

About

Several case reports indicate that the use of the antibiotic combination amoxicillin and clavulanic acid (AM-CLAVAC) can interact with warfarin pharmacodynamics. However, fever per se might also be responsible of these warfarin overdose reports, as well as the use of high dose paracetamol.

The aim of the present study is to determine if AM-CLAVAC can increase the pharmacodynamics of warfarin among patients at steady state Double blinded cross over controlled study vs placebo performed in 12 evaluable patients treated with warfarin with an INR target 2 to 3 and a stable INR and a stable dose.

Full description

Double blinded cross over controlled study vs placebo performed in 12 evaluable patients treated with warfarin with an INR target 2 to 3 and a stable INR and a stable dose

One period : seven consecutive days of amoxicillin(2g twice daily)- clavulanic acid (125 mg twice daily) association Wash out period of at least 4 weak with the return to a stable INR and warfarin dose One period : seven consecutive days of placebo twice daily

Main outcome INR delta Day7-Day

Enrollment

13 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients treated with warfarin (target INR 2 to 3)
  • stable anticoagulation (3 consecutive INR in the target)
  • stable dose
  • no infection
  • normal CRP
  • age >18 years
  • normal transaminase levels

Exclusion criteria

  • drug allergy
  • penicillin allergy
  • Alzheimer
  • cancer
  • thyroid disease
  • gastro intestinal chronic disease
  • frequent nausea or vomiting
  • Cirrhosis
  • chronic renal failure (GFR<60 ml/min)
  • frequent intake of paracetamol or NSAID
  • addict to drugs or alcool
  • St John's wort treatment or grapefruit juice intake
  • concomitant drugs (amiodarone, cimetidine, SSRI, clofibrate, fenofibrate, diltiazem, fluconazole, itraconazole, isoniazide, voriconazole, métronidazole, miconazole , omeprazole, glucocorticoids, zileuton, ritonavir, rifampicin, carbamazepine, phenytoin, phenobarbital)
  • antibiotic use during the 3 last weeks
  • pregnancy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

13 participants in 2 patient groups

1
Experimental group
Description:
Order 1 : Firstly Amoxicillin-Acid clavulanic, and Secondly Placebo
Treatment:
Drug: Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo
2
Experimental group
Description:
Order 2 : Firstly Placebo, and Secondly Amoxicillin-Acid clavulanic
Treatment:
Drug: Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems